Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Tidewater Inc (TDW) Price & Performance

AbbVie IncTrade
Tidewater IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Tidewater Inc — how do they compare? AbbVie Inc trades at $248.1 (market cap $441.94B), while Tidewater Inc trades at $91.72 (market cap $4.54B). The key difference: AbbVie Inc is far larger — about 97.3× Tidewater Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.

ABBVTDW
Market Cap
$441.94B$4.54B
Sector
HealthUtilities
52-Week High
$263.58$91.20
52-Week Low
$197.38$47.29
Enterprise Value
$506.19B$4.58B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.

Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.

Tidewater Inc

Tidewater (TDW) trades at $91.86, up 2.49% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 earnings of $0.43 per share, beating estimates (Zacks, August 3, 2026), though it missed expectations in prior quarters. Revenue for the quarter was $342.3 million, with net income margins around 18%. Analyst sentiment is mixed, with 26.92% recommending Buy and 57.7% Hold.

Outlook: Strong day rates and utilization support revenue growth, but earnings misses and Middle East operational costs pose risks. The stock's valuation (P/E 18.5) is reasonable, but investors face volatility from oil market exposure and execution challenges. Upside depends on sustained operational improvements and cost management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Tidewater Inc

Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.

Read more on TDW